Full-Time

Associate Director

Program & Alliance Management

Updated on 9/16/2026

Zymeworks

Zymeworks

201-500 employees

Biopharmaceutical firm developing multifunctional therapeutics

Compensation Overview

€90k - €138k/yr

Swords, Co. Dublin, Ireland

Hybrid

Hybrid with a minimum of 3 days on-site per week.

Bachelor's

Category
Project & Program Management (1)
Required Skills
Forecasting
Risk Management

Get referred to Zymeworks

See people who can refer or advise you

Requirements
  • A Bachelor's degree in biomedical sciences or another discipline related to life sciences and/or drug discovery.
  • At least ten years of related experience in the pharmaceutical or biotechnology industry.
  • Direct experience in a biopharmaceutical technical operations discipline and working knowledge of biologics drug development.
  • Experience working with and managing cross-functional teams.
  • Ability to collaborate effectively with staff and establish functional relationships with diverse internal and external stakeholders.
  • Ability to develop solutions to complex problems using ingenuity, creativity, and innovation.
  • Willingness to travel domestically and internationally approximately 10% of the time.
Responsibilities
  • Ensure program teams and operational activities remain aligned with corporate strategy, project timelines, and resource plans.
  • Provide input into management processes, critical path issues and solutions, resource management, and project management.
  • Foster relationships with team members and department leads while supporting project communications and issue identification and management.
  • Maintain program timelines, budgets, and tracking mechanisms for internal and external activities.
  • Track, monitor, and communicate contractual obligations, deliverables, and milestones.
  • Identify issues, lead conflict resolution, collaborate on solutions, and escalate matters to appropriate leadership when required.
  • Work with CMC, clinical, and research departments to execute development plans.
  • Collaborate with CMC team members to execute external manufacturing strategies.
  • Track development project timelines and activities to achieve deliverables, milestones, and regulatory filings aligned with company goals.
  • Work with cross-functional development team members, consultants, and vendors.
  • Develop, manage, and maintain high-level and detailed development-plan timelines, ensuring functional resources and forecasts align with project and program timelines.
  • Analyze and manage the critical path, evaluate acceleration or risk-mitigation options, and plan contingencies with input from relevant functions.
  • Communicate proactively with team members and monitor, track, and report project status to key stakeholders, including senior management.
  • Assess and mitigate project risks and create contingency plans with project teams.

Zymeworks develops multifunctional therapeutics for hard-to-treat cancers and other serious diseases. Its main products are antibody-drug conjugates (ADCs) and multispecific (bispecific) antibodies that link cancer targets to therapeutic payloads using proprietary platforms for precise engagement and modular design. The company drives discovery, preclinical work, and clinical development with an integrated R&D engine and earns revenue through partnerships, licensing, and commercialization of its own therapies. Its goal is to discover, develop, and commercialize novel therapeutic agents globally to improve outcomes for patients with difficult-to-treat cancers and other serious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2003

Get referred to Zymeworks

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of Ziihera on August 25, 2026 triggered a $250 million milestone for Zymeworks.
  • June 18, 2026 Gandeeva partnership improves antibody discovery against difficult targets.
  • August 4, 2026 FTC early termination reduced acquisition friction for Theravance’s pending purchase.

What critics are saying

  • August 25, 2026 revenue still depends on regulatory milestones and partner execution, not product sales.
  • Theravance closing remains subject to shareholder and regulatory approvals, delaying expected 2H 2026 cash flows.
  • ZW191 and pasritamig remain clinical-stage; a failed readout would crush platform credibility and valuation.

What makes Zymeworks unique

  • Ziihera and ZW191 prove Zymeworks’ Azymetric platform produces clinically active bispecifics.
  • J&J’s pasritamig program reached Phase 3 in 2025, validating Zymeworks’ discovery engine.
  • Theravance adds YUPELRI royalties and TRELEGY milestones, diversifying beyond oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Company Match

Company Equity

Paid Vacation

Hybrid Work Options

Remote Work Options

Employee Share Purchase Program

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 26th, 2026
SJM raises FY27 outlook to $10.50-$11/share after Q1 beat, ZYME surges on $250M FDA milestone

J.M. Smucker and Zymeworks shares reached 52-week highs on Wednesday following strong corporate developments. Smucker rose 4.1% after reporting first-quarter net sales of $2.2 billion, beating estimates of $2.13 billion. The food company raised its fiscal 2027 adjusted earnings forecast to between $10.50 and $11 per share, up from previous guidance of $9.75 to $10.25 per share. Zymeworks climbed 6%, hitting its highest level in nearly five years. The biotech firm received a $250 million milestone payment after the US Food and Drug Administration approved two Ziihera-based treatments for advanced HER2-positive gastroesophageal cancer. H.C. Wainwright raised Zymeworks' price target to $55 from $51, maintaining a buy rating.

MarketBeat
Aug 26th, 2026
Zymeworks (NASDAQ:ZYME) given "market outperform" Rating at Citizens Jmp.

Zymeworks (NASDAQ:ZYME) given "market outperform" Rating at Citizens Jmp. August 26, 2026 Key points. * Citizens JMP reiterated its "market outperform" rating on Zymeworks and maintained a $32 price target, implying 16.49% upside from the reported share price. * Analyst sentiment remains favorable overall, with nine Buy ratings, one Hold and one Sell; the consensus rating is "Moderate Buy" with an average price target of $40.22. * Zymeworks reported a quarterly loss of $0.62 per share versus the $0.56 expected and revenue of $3.23 million, down 90.6% year over year. The company also authorized a $125 million share buyback covering up to 7% of outstanding shares. * Interested in Zymeworks? Here are five stocks we like better. Zymeworks (NASDAQ:ZYME - Get Free Report)'s stock had its "market outperform" rating restated by investment analysts at Citizens Jmp in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $32.00 price objective on the stock. Citizens Jmp's price objective suggests a potential upside of 16.49% from the stock's current price. Several other research firms also recently issued reports on ZYME. HC Wainwright lifted their price target on Zymeworks from $51.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday. Wells Fargo & Company upped their price objective on Zymeworks from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Zymeworks in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of Zymeworks in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft set a $32.00 price objective on shares of Zymeworks in a report on Wednesday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $40.22. Zymeworks stock down 4.5%. Shares of ZYME stock opened at $27.47 on Wednesday. The firm has a fifty day moving average of $24.60 and a 200-day moving average of $24.72. Zymeworks has a 12-month low of $13.60 and a 12-month high of $30.50. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -13.60 and a beta of 1.15. Zymeworks (NASDAQ:ZYME - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The company had revenue of $3.23 million during the quarter, compared to the consensus estimate of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The company's revenue was down 90.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 earnings per share. On average, equities analysts expect that Zymeworks will post 1.25 EPS for the current year. Zymeworks announced that its Board of Directors has initiated a share buyback plan on Thursday, May 14th that permits the company to repurchase $125.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its shares are undervalued. Hedge funds weigh in on Zymeworks. A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Zymeworks during the 2nd quarter valued at $111,122,000. Siren L.L.C. bought a new position in Zymeworks in the fourth quarter valued at about $44,238,000. Rubric Capital Management LP boosted its stake in shares of Zymeworks by 21.7% during the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock valued at $175,280,000 after purchasing an additional 1,250,000 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Zymeworks by 56.0% during the fourth quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company's stock valued at $85,885,000 after purchasing an additional 1,171,187 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Zymeworks by 851.6% during the third quarter. Millennium Management LLC now owns 1,104,813 shares of the company's stock valued at $18,870,000 after purchasing an additional 988,711 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock. About Zymeworks. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity. At the core of Zymeworks' innovation is its Azymetric(TM) bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Zymeworks, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list. While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

GlobeNewswire
Aug 11th, 2026
Zymeworks announces participation in upcoming investor conferences.

Zymeworks announces participation in upcoming investor conferences. August 11, 2026 06:00 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: * Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA. * Citi's Biopharma Back to School Summit: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY. * Morgan Stanley Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 14 at 4:50 pm ET in New York, NY. * H.C. Wainwright Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 15 in New York, NY. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected] Company Profile Zymeworks Inc. Industry: Pharmaceuticals & Biotechnology Website: https://www.zymeworks.com/ Recommended reading.

Zymeworks Inc.
Aug 11th, 2026
Zymeworks announces participation in upcoming investor conferences.

Zymeworks announces participation in upcoming investor conferences. August 11, 2026 VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: * Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA. * Citi's Biopharma Back to School Summit: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY. * Morgan Stanley Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 14 at 4:50 pm ET in New York, NY. * H.C. Wainwright Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 15 at 3:30 pm ET in New York, NY. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected]

PR Newswire
Aug 10th, 2026
Zymeworks to acquire Theravance Biopharma for $17 per share in cash plus CVR

Theravance Biopharma reported second quarter 2026 financial results, showing progress on its pending acquisition by Zymeworks expected to close in the second half of 2026 for $17.00 per share in cash. YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million, driven by continued net sales growth. The company's organizational restructuring delivered a 35% reduction in operating expenses year-over-year, excluding restructuring and transaction costs. TRELEGY net sales reached approximately $1.0 billion in Q2 2026, reported by GSK. The company expressed high confidence in achieving a $100 million 2026 milestone payment. Theravance Biopharma ended the quarter with a cash balance of $388 million and no debt. The company reported a net loss of $5.9 million for the quarter, compared to net income of $54.8 million in Q2 2025.